The age-related eye disease 2 study: Micronutrients in the treatment of macular degeneration

Advances in Nutrition

Volumn 8, Issue 1, 2017, Pages 40-53

  Gorusupudi, Aruna ^a   Nelson, Kelly ^a   Bernstein, Paul S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

AMD; AREDS2; Micronutrients; N 3 LC PUFAs; Xanthophylls; carotene

Indexed keywords

ANTIOXIDANT; TRACE ELEMENT; XANTHOPHYLL; ZEAXANTHIN;

AGING; DIET; DIETARY SUPPLEMENT; DOSE RESPONSE; HUMAN; INCIDENCE; MACULAR DEGENERATION; META ANALYSIS (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGING; ANTIOXIDANTS; DIET; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INCIDENCE; LUTEIN; MACULAR DEGENERATION; META-ANALYSIS AS TOPIC; MICRONUTRIENTS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ZEAXANTHINS;

EID: 85011300294     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.116.013177     Document Type: Review

References (155)

1. Bourne RRA, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Parodi MB, Pesudovs K, Price H, White RA, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol 2014;98:629-38.
2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health 2013;1:e339-49.
3. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-16.
4. Mayne ST. Beta-carotene, carotenoids, and disease prevention in humans. FASEB J 1996;10:690-701.
5. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999;5:32.
6. Gass JD. Drusen and disciform macular detachment and degeneration. Trans Am Ophthalmol Soc 1972;70:409-36.
7. Sarks SH, Van Driel D, Maxwell L, Killingsworth M. Softening of drusen and subretinal neovascularization. Trans Ophthalmol Soc U K 1980;100:414-22.
8. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 1999;44:1-29.
9. Green WR, Key SN 3rd. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 1977;75:180-254.
10. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-93.
11. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986;93:1169-76.
12. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-2.
13. Olsen TW, Knobloch WH. Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 2007; 144:281-3.
14. Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, Campochiaro PA. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am J Ophthalmol 2015;159:9-19. e2.
15. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1.
16. Klein R, Chou C-F, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 2011;129:75-80.
17. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; The Eye Diseases Prevalence Research G. Prevalence of age-related macular degeneration in the united states. Arch Ophthalmol 2004;122:564-72.
18. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001;20:227-53.
19. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697-704.
20. Vinding T. Age-related macular degeneration. Macular changes, prevalence and sex ratio. An epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh) 1989;67:609-16.
21. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CFL, de Jong PTVM. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 1995;102:205-10.
22. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. Ophthalmology 1992;99:933-43.
23. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of agerelated maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002;109:1092-7.
24. Klein R, Klein BEK, Marino EK, Kuller LH, Furberg C, Burke GL, Hubbard LD. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003;110:25-33.
25. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration. Ophthalmology 1999;106:1049-55.
26. Hyman LG, Lilienfeld AM, Ferris FL, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol 1983;118:213-27.
27. Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and agerelated maculopathy: the Blue Mountains Eye Study. Ophthalmology 1998;105:1359-63.
28. Klein R, Klein BE, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol 1998;116:506-13.
29. Hirakawa M, Tanaka M, Tanaka Y, Okubo A, Koriyama C, Tsuji M, Akiba S, Miyamoto K, Hillebrand G, Yamashita T, et al. Age-related maculopathy and sunlight exposure evaluated by objective measurement. Br J Ophthalmol 2008;92:630-4.
30. Klein RJ, Zeiss C, Chew EY, Tsai J-Y, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9.
31. Donoso LA, Vrabec T, Kuivaniemi H. The role of complement Factor H in age-related macular degeneration: a review. Surv Ophthalmol 2010;55:227-46.
32. Hadley D, Orlin A, Brown G, Brucker AJ, Ho AC, Regillo CD, Donoso LA, Tian L, Kaderli B, Stambolian D. Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26. Invest Ophthalmol Vis Sci 2010;51:2191-6.
33. Gibbs D, Yang Z, Constantine R, Ma X, Camp NJ, Yang X, Chen H, Jorgenson A, Hau V, DeWan A, et al. Further mapping of 10q26 supports strong association of HTRA1 polymorphisms with agerelated macular degeneration. Vision Res 2008;48:685-9.
34. van Lookeren Campagne M, Strauss EC, Yaspan BL. Age-related macular degeneration: complement in action. Immunobiology 2016;221:733-9.
35. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC. Genetic Factors in AMDS. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006;90:75-80.
36. Delcourt C, Carriere I, Ponton-Sanchez A, Fourrey S, Lacroux A, Papoz L. Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liees a l'Age (POLA) study. Arch Ophthalmol 2001;119:1463-8.
37. Fletcher AE, Bentham GC, Agnew M, Young IS, Augood C, Chakravarthy U, de Jong PT, Rahu M, Seland J, Soubrane G, et al. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol 2008;126:1396-403.
38. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 1989;107:847-52.
39. Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. Arch Ophthalmol 1993; 111:514-8.
40. Boulton M, Docchio F, Dayhaw-Barker P, Ramponi R, Cubeddu R. Age-related changes in the morphology, absorption and fluorescence of melanosomes and lipofuscin granules of the retinal pigment epithelium. Vision Res 1990;30:1291-303.
41. Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao DY, Katz NB. Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp Eye Res 2001;72:215-23.
42. Bhosale P, Serban B, Bernstein PS. Retinal carotenoids can attenuate formation of A2E in the retinal pigment epithelium. Arch Biochem Biophys 2009;483:175-81.
43. Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci 2000;41:1981-9.
44. Conn PF, Schalch W, Truscott TG. The singlet oxygen and carotenoid interaction. J Photochem Photobiol B 1991;11:41-7.
45. Jarrett SG, Boulton ME. Consequences of oxidative stress in agerelated macular degeneration. Mol Aspects Med 2012;33:399-417.
46. Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group. Arch Ophthalmol 1993;111: 104-9. Erratum in: Arch Ophthalmol 1993;111:1499; 111:1228; 111: 1366.
47. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001;42:235-40.
48. Bernstein PS, Li B, Vachali PP, Gorusupudi A, Shyam R, Henriksen BS, Nolan JM. Lutein, zeaxanthin, and meso-zeaxanthin: the basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res 2016;50:34-66.
49. Newsome DA, Swartz M, Leone NC, Elston RC, Miller E. Oral zinc in macular degeneration. Arch Ophthalmol 1988;106:192-8.
50. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272: 1413-20.
51. West S, Vitale S, Hallfrisch J, Muñoz B, Muller D, Bressler S, Bressler NM. Are antioxidants or supplements protective for agerelated macular degeneration? Arch Ophthalmol 1994;112:222-7.
52. Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, Albanes D, Taylor P, Heinonen OP. Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy. Acta Ophthalmol Scand 1998;76:224-9.
53. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 1998;148:204-14.
54. Christen WG, Ajani UA, Glynn RJ, Manson JE, Schaumberg DA, Chew EC, Buring JE, Hennekens CH. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. Am J Epidemiol 1999;149:476-84.
55. Smith W, Mitchell P, Webb K, Leeder SR. Dietary antioxidants and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 1999;106:761-7.
56. Age-Related Eye Disease Study Research Group. A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol 2001;119:1417-36.
57. Cho E, Hung S, Willett WC, Spiegelman D, Rimm EB, Seddon JM, Colditz GA, Hankinson SE. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 2001;73:209-18.
58. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 2001;153:424-32.
59. Seddon JM, Rosner B, Sperduto RD, Yannuzzi L, Haller JA, Blair NP, Willett W. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 2001;119:1191-9.
60. Gale CR, Hall NF, Phillips DIW, Martyn CN. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2461-5.
61. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, TsipurskyM, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216-30.
62. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT. Dietary intake of antioxidants and risk of agerelated macular degeneration. JAMA 2005;294:3101-7.
63. Delcourt C, Carrière I, Delage M, Barberger-Gateau P, Schalch W. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA study. Invest Ophthalmol Vis Sci 2006;47:2329-35.
64. Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB, Mares JA; CAREDS Research Study Group. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the carotenoids in Age-Related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol 2006;124:1151-62.
65. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: The US twin study of age-related macular degeneration. Arch Ophthalmol 2006;124:995-1001.
66. Age-Related Eye Disease Study Research Group; SanGiovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007;125:1225-32.
67. Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, Fobker M, PauleikhoffD. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res 2007;84:718-28.
68. Cho E, Hankinson SE, Rosner B, Willett WC, Colditz GA. Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. Am J Clin Nutr 2008;87:1837-43.
69. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008; 115:334-41.
70. Parekh N, Voland RP, Moeller SM, Blodi BA, Ritenbaugh C, Chappell RJ, Wallace RB, Mares JA; CAREDS Research Study Group. Association between dietary fat intake and age-related macular degeneration in the carotenoids in Age-Related Eye Disease Study (CAREDS): An ancillary study of the women's health initiative. Arch Ophthalmol 2009;127:1483-93.
71. Merle BM, Delyfer M-N, Korobelnik J-F, Rougier M-B, Malet F, Féart C, Le GoffM, Peuchant E, Letenneur L, Dartigues J-F. High concentrations of plasma n3 fatty acids are associated with decreased risk for late agerelated macular degeneration. J Nutr 2013;143:505-11.
72. Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, Smith T, Benlian P. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 Study. Ophthalmology 2013;120:1619-31.
73. Dawczynski J, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J. Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Arch Clin Exp Ophthalmol 2013;251:2711-23.
74. Blasiak J, Szaflik J, Szaflik JP. Implications of altered iron homeostasis for age-related macular degeneration. Front Biosci (Landmark Ed) 2011;16:1551-9.
75. Chen H, Liu B, Lukas TJ, Suyeoka G, Wu G, Neufeld AH. Changes in iron-regulatory proteins in the aged rodent neural retina. Neurobiol Aging 2009;30:1865-76.
76. Ugarte M, Osborne NN, Brown LA, Bishop PN. Iron, zinc, and copper in retinal physiology and disease. Surv Ophthalmol 2013;58: 585-609.
77. Andrzejczyk J, Buszman E. Interaction of Fe3+, Cu2+ and Zn2+ with melanin and melanoproteins from bovine eyes. Acta Biochim Pol 1992;39:85-8.
78. Bowness JM, Morton RA, Shakir MH, Stubbs AL. Distribution of copper and zinc in mammalian eyes. Occurrence of metals in melanin fractions from eye tissues. Biochem J 1952;51:521.
79. Erie JC, Good JA, Butz JA, Pulido JS. Reduced zinc and copper in the retinal pigment epithelium and choroid in age-related macular degeneration. Am J Ophthalmol 2009;147:276-82.e1.
80. Naismith RT, Shepherd JB, Weihl CC, Tutlam NT, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol 2009;66:1025-7.
81. Pineles SL, Wilson CA, Balcer LJ, Slater R, Galetta SL. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol 2010;55:386-92.
82. Park SJ, Lee JH, Woo SJ, Kang SW, Park KH. Five heavy metallic elements and age-related macular degeneration. Ophthalmology 2015; 122:129-37.
83. Tokarz P, Kaarniranta K, Blasiak J. Role of antioxidant enzymes and small molecular weight antioxidants in the pathogenesis of age-related macular degeneration (AMD). Biogerontology 2013;14:461-82.
84. Gotoh N, Yamada R, Matsuda F, Yoshimura N, Iida T. Manganese superoxide dismutase gene (SOD2) polymorphism and exudative agerelated macular degeneration in the Japanese population. Am J Ophthalmol 2008;146:author reply146-7.
85. Mayer MJ, van Kuijk FJ, Ward B, Glucs A. Whole blood selenium in exudative age-related maculopathy. Acta Ophthalmol Scand 1998;76: 62-7.
86. Nielsen JC, Naash MI, Anderson RE. The regional distribution of vitamins E and C in mature and premature human retinas. Invest Ophthalmol Vis Sci 1988;29:22-6.
87. Wiegand RD, Joel CD, Rapp LM, Nielsen JC, Maude MB, Anderson RE. Polyunsaturated fatty acids and vitamin E in rat rod outer segments during light damage. Invest Ophthalmol Vis Sci 1986;27:727-33.
88. Robison WG Jr., Kuwabara T, Bieri JG. The roles of vitamin E and unsaturated fatty acids in the visual process. Retina 1982;2:263-81.
89. Tanito M, Yoshida Y, Kaidzu S, Chen Z-H, Cynshi O, Jishage K-i, Niki E, Ohira A. Acceleration of age-related changes in the retina in a-tocopherol transfer protein null mice fed a vitamin E-deficient diet. Invest Ophthalmol Vis Sci 2007;48:396-404.
90. Katz ML, Eldred GE. Failure of vitamin E to protect the retina against damage resulting from bright cyclic light exposure. Invest Ophthalmol Vis Sci 1989;30:29-36.
91. Katz ML, Eldred GE. Retinal light damage reduces autofluorescent pigment deposition in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1989;30:37-43.
92. Belda JI. Romá J, Vilela C, Puertas FJ, Díaz-Llopis M, Bosch-Morell F, Romero FJ. Serum vitamin E levels negatively correlate with severity of age-related macular degeneration. Mech Ageing Dev 1999;107:159-64.
93. Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ. Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 2002;325:11.
94. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 2009;169:335-41.
95. Gopinath B, Flood VM, Rochtchina E, Wang JJ, Mitchell P. Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration. Am J Clin Nutr 2013;98:129-35.
96. Britton G. Structure and properties of carotenoids in relation to function. FASEB J 1995;9:1551-8.
97. Stahl W, Nicolai S, Briviba K, Hanusch M, Broszeit G, Peters M, Martin HD, Sies H. Biological activities of natural and synthetic carotenoids: induction of gap junctional communication and singlet oxygen quenching. Carcinogenesis 1997;18:89-92.
98. Burton GW, Ingold KU. beta-Carotene: an unusual type of lipid antioxidant. Science 1984;224:569-73.
99. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr., Valanis B, Williams JH Jr., et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-9.
100. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards B, Haapakoski J, Rautalahti M, Hartman A, Palmgren J. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995;62:1427S-30S.
101. Cerutti PA. Oxy-radicals and cancer. Lancet 1994;344:862-3.
102. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris, FL 3rd; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112:533-9.
103. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119:1439-52.
104. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, Hartman AM, Palmgren J, Freedman LS, Haapakoski J, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70.
105. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
106. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Invest Ophthalmol Vis Sci 1993; 34:2033-40.
107. Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci 1988;29:843-9.
108. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 1995;62:1448S-61S.
109. Khachik F, de Moura FF, Zhao DY, Aebischer CP, Bernstein PS. Transformations of selected carotenoids in plasma, liver, and ocular tissues of humans and in nonprimate animal models. Invest Ophthalmol Vis Sci 2002;43:3383-92.
110. Sundelin SP, Nilsson SE. Lipofuscin-formation in retinal pigment epithelial cells is reduced by antioxidants. Free Radic Biol Med 2001;31: 217-25.
111. Hammond BR Jr., Wooten BR, Curran-Celentano J. Carotenoids in the retina and lens: possible acute and chronic effects on human visual performance. Arch Biochem Biophys 2001;385:41-6.
112. Stringham JM, Hammond BR. Macular pigment and visual performance under glare conditions. Optom Vis Sci 2008;85:82-8.
113. Li B, Vachali P, Frederick JM, Bernstein PS. Identification of StARD3 as a lutein-binding protein in the macula of the primate retina. Biochemistry 2011;50:2541-9.
114. Bhosale P, Larson AJ, Frederick JM, Southwick K, Thulin CD, Bernstein PS. Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye. J Biol Chem 2004;279:49447-54.
115. Reboul E, Richelle M, Perrot E, Desmoulins-Malezet C, Pirisi V, Borel P. Bioaccessibility of carotenoids and vitamin E from their main dietary sources. J Agric Food Chem 2006;54:8749-55.
116. Bohn T. Bioavailability of non-provitamin A carotenoids. Curr Nutr Food Sci 2008;4:240-58.
117. Wang W, Connor SL, Johnson EJ, Klein ML, Hughes S, Connor WE. Effect of dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in age-related macular degeneration. Am J Clin Nutr 2007;85:762-9.
118. Garrett DA, Failla ML, Sarama RJ, Craft N. Accumulation and retention of micellar b-carotene and lutein by Caco-2 human intestinal cells. J Nutr Biochem 1999;10:573-81.
119. van den Berg H, van Vliet T. Effect of simultaneous, single oral doses of beta-carotene with lutein or lycopene on the beta-carotene and retinyl ester responses in the triacylglycerol-rich lipoprotein fraction of men. Am J Clin Nutr 1998;68:82-9.
120. Faulks RM, Southon S. Challenges to understanding and measuring carotenoid bioavailability. Biochim Biophys Acta 2005; 1740:95-100.
121. Wang Y, Illingworth DR, Connor SL, Duell PB, Connor WE. Competitive inhibition of carotenoid transport and tissue concentrations by high dose supplements of lutein, zeaxanthin and beta-carotene. Eur J Nutr 2010;49:327-36.
122. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005;24:87-138.
123. Lorente-Cebrián S, Costa AGV, Navas-Carretero S, Zabala M, Laiglesia LM, Martínez JA, Moreno-Aliaga MJ. An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. J Physiol Biochem 2015;71:341-9.
124. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999;70:560S-9S.
125. Nestel P, Clifton P, Colquhoun D, Noakes M, Mori TA, Sullivan D, Thomas B. Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. Heart Lung Circ 2015;24:769-79.
126. EFSA Panel on Dietetic Products Nutrition, and Allergies. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J 2010;8: 1461.
127. SanGiovanni JP, Chew EY, Agron E, Clemons TE, Ferris FL, Gensler G, Lindblad AS, Milton RC, Seddon JM, Klein R. The relationship of dietary v-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol 2008;126:1274-9.
128. SanGiovanni J, Chew E, Clemons T, Seddon J, Klein R, AREDS Research. Dietary lipid intake and incident advanced age-related macular degeneration (AMD) in the Age-Related Eye Disease Study (AREDS). Invest Ophthalmol Vis Sci 2005;46:2382.
129. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 2009;50:S400-5.
130. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006;51:137-52.
131. Delyfer M-N, Buaud B, Korobelnik J-F, Rougier M-B, Schalch W, Etheve S, Vaysse C, Combe N, Le GoffM, Wolf-Schnurrbusch UE. Association of macular pigment density with plasma omega-3 fatty acids: the PIMAVOSA study. Invest Ophthalmol Vis Sci 2012;53: 1204-10.
132. Wang JJ, Rochtchina E, Smith W, Klein R, Klein BE, Joshi T, Sivakumaran TA, Iyengar S, Mitchell P. Combined effects of complement factor H genotypes, fish consumption, and inflammatory markers on long-term risk for age-related macular degeneration in a cohort. Am J Epidemiol 2009;169:633-41.
133. Augood C, Chakravarthy U, Young I, Vioque J, de Jong PT, Bentham G, Rahu M, Seland J, Soubrane G, Tomazzoli L. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr 2008;88:398-406.
134. Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2009;127:656-65.
135. SanGiovanni JP, Agrón E, Clemons TE, Chew EY. v-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration. Arch Ophthalmol 2009;127:110-2.
136. Koto T, Nagai N, Mochimaru H, Kurihara T, Izumi-Nagai K, Satofuka S, Shinoda H, Noda K, Ozawa Y, Inoue M. Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice. Invest Ophthalmol Vis Sci 2007;48:4328-34.
137. Gorusupudi A, Liu A, Hageman GS, Bernstein PS. Associations of human retinal very long-chain polyunsaturated fatty acids with dietary lipid biomarkers. J Lipid Res 2016;57:499-508.
138. Querques G, Benlian P, Chanu B, Portal C, Coscas G, Soubrane G, Souied E. Nutritional AMD treatment phase I (NAT-1): feasibility of oral DHA supplementation in age-related macular degeneration. Eur J Ophthalmol 2009;19:100.
139. Rosenthal JM, Kim J, de Monasterio F, Thompson DJ, Bone RA, Landrum JT, de Moura FF, Khachik F, Chen H, Schleicher RL, et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. Invest Ophthalmol Vis Sci 2006;47:5227-33. Erratum in: Invest Ophthalmol Vis Sci 2007;48:14.
140. Johnson AR, Munoz A, Gottlieb JL, Jarrard DF. High dose zinc increases hospital admissions due to genitourinary complications. J Urol 2007;177:639-43.
141. AREDS2 Research Group, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, Sperduto R, Ferris FL. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 2012; 119:2282-9.
142. Bernstein PS, Ahmed F, Liu A, Allman S, Sheng X, Sharifzadeh M, Ermakov I, Gellermann W. Macular pigment imaging in AREDS2 participants: an ancillary study of AREDS2 subjects enrolled at the Moran Eye Center. Invest Ophthalmol Vis Sci 2012;53:6178-86.
143. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005-15.Erratum in: JAMA 2013;310:208.
144. Age-Related Eye Disease Study 2 Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL III, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 2014;132:142-9.
145. van Het Hof KH, West CE, Weststrate JA, Hautvast JG. Dietary factors that affect the bioavailability of carotenoids. J Nutr 2000;130:503-6.
146. Meyers KJ, Liu Z, Millen AE, Iyengar SK, Blodi BA, Johnson E, Snodderly DM, Klein ML, Gehrs KM, Tinker L, et al. Joint associations of diet, lifestyle, and genes with age-related macular degeneration. Ophthalmology 2015;122:2286-94.
147. Wang JJ, Buitendijk GHS, Rochtchina E, Lee KE, Klein BEK, van Duijn CM, Flood VM, Meuer SM, Attia J, Myers C, et al. Genetic susceptibility, dietary antioxidants, and long-term incidence of agerelated macular degeneration in two populations. Ophthalmology 2014;121:667-75.
148. Merle B, Delyfer MN, Korobelnik JF, Rougier MB, Colin J, Malet F, Feart C, Le GoffM, Dartigues JF, Barberger-Gateau P, et al. Dietary omega-3 fatty acids and the risk for age-related maculopathy: the Alienor Study. Invest Ophthalmol Vis Sci 2011;52:6004-11.
149. Awh CC, Hawken S, Zanke BW. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology 2015;122:162-9.
150. Chew EY, Klein ML, Clemons TE, Agron E, Abecasis GR. Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? Ophthalmology 2015;122:212-5.
151. van der Made SM, Kelly ER, Kijlstra A, Plat J, Berendschot TTJM. Increased macular pigment optical density and visual acuity following consumption of a buttermilk drink containing lutein-enriched egg yolks: a randomized, double-blind, placebo-controlled trial. J Ophthalmol 2016;2016:9035745.
152. Ma L, Yan SF, Huang YM, Lu XR, Qian F, Pang HL, Xu XR, Zou ZY, Dong PC, Xiao X, et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology 2012;119:2290-7.
153. Cheng CY, Chung WY, Szeto YT, Benzie IF. Fasting plasma zeaxanthin response to Fructus barbarum L.(wolfberry; Kei Tze) in a food-based human supplementation trial. Br J Nutr 2005;93:123-30.
154. Piccardi M, Marangoni D, Minnella A, Savastano MC, Valentini P, Ambrosio L, Capoluongo E, Maccarone R, Bisti S, Falsini B. A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function. Evid Based Complement Alternat Med 2012;2012:429124.
155. Liu Y, Song X, Zhang D, Zhou F, Wang D, Wei Y, Gao F, Xie L, Jia G, Wu W. Blueberry anthocyanins: protection against ageing and lightinduced damage in retinal pigment epithelial cells. Br J Nutr 2012; 108:16-27.